Humanetix among recipients of ANDHealth+ commercialisation program

Five promising Australian digital health companies have been chosen for the prestigious ANDHealth+ commercialisation program, offering them up to $3.75 million in equity-free funding and expert support for national and international scaling.

ANDHealth+ is a flagship initiative funded by the Medical Research Future Fund, aiding digital health commercialisation. Recipients include Humanteix

ANDHealth CEO and Managing Director, Bronwyn Le Grice said, “ANDHealth+ is a highly competitive program and the selection panel has been impressed by the continual improvement in the quality of applications over time.” 

“These five exceptional companies will receive highly targeted expert advice and mentoring from international industry leaders, specialised commercialisation expertise, and significant non-dilutive investment to generate the clinical and commercial evidence required to scale their digital health products and services nationally and internationally,” Ms Le Grice added.  The companies selected include:

Atmo Biosciences: Australian digital health firm commercialising the world’s first gas-sensing capsule. The capsule measures gaseous biomarkers in the gut, aiding gut health insights, personalized treatments, and relief for gastrointestinal issues in clinical trials worldwide.

Eugene: Enabling genetic testing access and informed health choices. By automating 95% of specialist clinical care through virtual models, Eugene addresses the shortage of clinical specialists. Their at-home medical-grade genetic testing service empowers over 13,000 individuals in reproductive and preventive health decisions.

Humanetix (HX): Simplifying care via technology. HX Health’s patented AI care engine offers clinical workflows and smart actions based on 160+ health identifiers, unburdening healthcare professionals from administration. With 400+ adaptable clinical pathways, caregivers deliver personalized care effectively.

Immunosis: Clinical stage startup developing diagnostic products for life-threatening immune deficiencies. Their test integrates gene expression data and mutation information from whole blood samples, aiding clinicians in diagnosing and treating immune deficiencies.

Metabolic Health Solutions (MHS): Empowering practitioners for improved metabolic health outcomes. As an ISO13485 manufacturer, MHS innovates measurement-informed obesity solutions through clinics worldwide, enhancing weight loss and care quality with its Digital Health Platform ENABLE.

The companies were selected based on their potential for growth, innovation, and impact.

They will receive expert advice, mentoring, and investment to bolster clinical and commercial evidence and expand their digital health products and services.

Past ANDHealth+ cohorts have raised $148 million in funding, generated $49 million in revenue, and positively impacted patients.

The program aims to foster growth, innovation, and meaningful change within Australia’s digital health landscape, ultimately transforming patient care and well-being.

LEAVE A REPLY

Please enter your comment!
Please enter your name here